Expansion Opportunity Olpha is expanding its footprint in Europe with a new generic cardiology medication launch and ongoing investments in pharmaceutical manufacturing equipment in Latvia and Northern Europe, signaling opportunities for contract manufacturing, distribution partnerships, and regional supply agreements.

Dermal and API Demand With a portfolio spanning over 60 FDFs, 25 APIs and a focus on neurology, cardiology, infectology, and allergology, there is potential to target API supply, formulation development, and specialty contract manufacturing for related therapeutic areas and high-demand generics.

Technical Excellence Olpha leverages advanced chemistry expertise in adamantane, quinuclidine and nitrofurane chemistry and holds EU GMP, FDA cGMP, TGA and ISO certifications, creating opportunities to offer compliant manufacturing services, tech transfer, and quality-focused collaborations for regulated markets.

Leadership Continuity With Juris Bundulis serving as Chairman of the Management Board and the company asserting a long-standing history, there is credibility for executive-led partnerships, strategic alliances, and long-term supply commitments that can reassure potential customers and suppliers.

Scale and Capacity Recent capital investments in manufacturing equipment and a revenue range in the hundreds of millions position Olpha as a scalable supplier for regional customers seeking reliable capacity, pace of delivery, and integrated supply chain solutions across Europe.